Top

Current Hepatology Reports

Published in:

Open Access 21-02-2024 | Hepatitis B | Review

Hepatitis B Virus Elimination Strategies

Authors: Mimi Xu, Norah A. Terrault

Published in: Current Hepatology Reports | Issue 2/2024

Abstract

Purpose of Review

The World Health Assembly called to eliminate viral hepatitis as a public health threat in 2016 and proposed elimination goals by 2030. This review examined current national and global progress with hepatitis B virus elimination, and the hurdles and solutions being undertaken to achieve elimination goals.

Recent Findings

Few countries are on target to achieve the elimination targets of a 95% reduction in new infections and a 65% reduction in mortality by 2030. Gaps towards elimination remain, such as low infant vaccine coverage in low-income countries and continued under-diagnosis and low rates of treatment globally.

Summary

HBV elimination is feasible but will require continued focus on infant and childhood vaccine coverage, improving blood and injection safety, increasing harm reduction measures among persons who use drugs, and providing broader access to low-cost diagnostics and antiviral treatment.

• Razavi-Shearer D, Gamkrelidze I, Pan C, Jia J, Berg T, Gray R, et al. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. Lancet GastroenterolHepatol [Internet]. 2023 Jul 27 [cited 2023 Aug 9]; Available from: https://www.sciencedirect.com/science/article/pii/S2468125323001978. This provides estimates of country, regional, and global prevalence of hepatitis B virus infection in 2022 and the effects of treatment and prevention on disease burden.

Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022–2030 [Internet]. [cited 2023 Aug 7]. Available from: https://www.who.int/publications-detail-redirect/9789240053779

Global hepatitis report, 2017 [Internet]. [cited 2022 Jun 22]. Available from: https://www-who-int.libproxy2.usc.edu/publications-detail-redirect/9789241565455

Lan Y, Wang H, Weng H, Xu X, Yu X, Tu H, et al. The burden of liver cirrhosis and underlying etiologies: results from the Global Burden of Disease Study 2019. Hepatol Commun. 2023;7(2):e0026.PubMedPubMedCentralCrossRef

Choi S, Kim BK, Yon DK, Lee SW, Lee HG, Chang HH, et al. Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: a DALY-based analysis of the Global Burden of Disease 2019 study. Clin Mol Hepatol. 2023;29(2):433–52.PubMedPubMedCentralCrossRef

Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022;7(9):796–829.

Global health sector strategies on HIV, hepatitis and STIs 2016–2021 [Internet]. [cited 2023 Aug 7]. Available from: https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/strategies/global-health-sector-strategies-2016-2021

Interim guidance for country validation of viral hepatitis elimination [Internet]. [cited 2023 Sep 10]. Available from: https://www-who-int.libproxy2.usc.edu/publications-detail-redirect/9789240028395

Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–99.PubMedCrossRef

10.

Consolidated strategic information guidelines for viral hepatitis planning and tracking progress towards elimination: guidelines [Internet]. [cited 2023 Aug 13]. Available from: https://www.who.int/publications/i/item/9789241515191

11.

Interpretation of hepatitis B serologic test results | CDC [Internet]. 2023 [cited 2023 Aug 13]. Available from: https://www.cdc.gov/hepatitis/hbv/interpretationOfHepBSerologicResults.htm

12.

•• Cui F, Blach S, Manzengo MC, Gonzalez MA, Sabry AA, Mozalevskis A, et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol Hepatol. 2023;8(4):332–42. This details the global progress towards hepatitis elimination, gaps in data availability or quality, and suggests a new mechanism to monitor the progress of elimination.PubMedCrossRef

13.

Bixler D, Barker L, Lewis K, Peretz L, Teshale E. Prevalence and awareness of hepatitis B virus infection in the United States: January 2017 - March 2020. Hepatol Commun. 2023;7(4):e0118.PubMedPubMedCentralCrossRef

14.

• Wong RJ, Brosgart CL, Welch S, Block T, Chen M, Cohen C, et al. An updated assessment of chronic hepatitis B prevalence among foreign‐born persons living in the United States. Hepatol Baltim Md. 2021;74(2):607–26. This reference estimates the number of foreign-born persons with chronic hepatitis B in the United States.CrossRef

15.

Le MH, Yeo YH, Cheung R, Henry L, Lok AS, Nguyen MH. Chronic hepatitis B prevalence among foreign-born and U.S.-born adults in the United States, 1999–2016. Hepatol Baltim Md. 2020;71(2):431–43.CrossRef

16.

•• Schillie S. Prevention of hepatitis B virus infection in the United States: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep [Internet]. 2018 [cited 2023 Aug 13];67. Available from: https://www.cdc.gov/mmwr/volumes/67/rr/rr6701a1.htm. These are recommendations from the Advisory Committee on Immunization Practices and CDC regarding the prevention of HBV infection in the United States.

17.

Su S, Wong WC, Zou Z, Cheng DD, Ong JJ, Chan P, et al. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation. Lancet Glob Health. 2022;10(2):e278–87.PubMedPubMedCentralCrossRef

18.

Beckett GA, Ramirez G, Vanderhoff A, Nichols K, Chute SM, Wyles DL, et al. Early identification and linkage to care of persons with chronic hepatitis B virus infection — three U.S. sites, 2012–2014. Morb Mortal Wkly Rep. 2014;63(18):399–401.

19.

Toy M, Wei B, Virdi TS, Le A, Trinh H, Li J, et al. Racial/ethnic- and county-specific prevalence of chronic hepatitis B and its burden in California. Hepatol Med Policy. 2018;5(3):6.CrossRef

20.

Sullivan RP, Davies J, Binks P, Dhurrkay RG, Gurruwiwi GG, Bukulatjpi SM, et al. Point of care and oral fluid hepatitis B testing in remote Indigenous communities of northern Australia. J Viral Hepat. 2020;27(4):407–14.PubMedCrossRef

21.

Jin D, Brener L, Treloar C. Hepatitis B-related stigma among Chinese immigrants living with hepatitis B virus in Australia: a qualitative study. Health Soc Care Community. 2022;30(6):e5602–11.PubMedPubMedCentralCrossRef

22.

Yoo GJ, Fang T, Zola J, Dariotis WM. Destigmatizing hepatitis B in the Asian American community: lessons learned from the San Francisco Hep B Free Campaign. J Cancer Educ Off J Am Assoc Cancer Educ. 2012;27(1):138.

23.

Consolidated guidelines on HIV, viral hepatitis and STI for key populations - 2022 [Internet]. [cited 2023 Aug 14]. Available from: https://www.who.int/publications-detail-redirect/9789240052390

24.

Lanini S, Ustianowski A, Pisapia R, Zumla A, Ippolito G. Viral hepatitis: etiology, epidemiology, transmission, diagnostics, treatment, and prevention. Infect Dis Clin North Am. 2019;33(4):1045–62.PubMedCrossRef

25.

Chien YC, Jan CF, Kuo HS, Chen CJ. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev. 2006;28(1):126–35.PubMedCrossRef

26.

Cui F, Shen L, Li L, Wang H, Wang F, Bi S, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China - Volume 23, Number 5—May 2017 - Emerging Infectious Diseases journal - CDC. [cited 2023 Sep 10]; Available from: https://wwwnc.cdc.gov/eid/article/23/5/16-1477_article

27.

Hutton DW, Toy M, Salomon JA, Conners EE, Nelson NP, Harris AM, et al. Cost-effectiveness of hepatitis B testing and vaccination of adults seeking care for sexually transmitted infections. Sex Transm Dis. 2022;49(7):517–25.PubMedPubMedCentralCrossRef

28.

•• Weng MK, Doshani M, Khan MA, Frey S, Ault K, Moore KL, et al. Universal hepatitis B vaccination in adults aged 19–59 years: updated recommendations of the Advisory Committee on Immunization Practices — United States, 2022. Morb Mortal Wkly Rep. 2022;71(13):477–83. This provides the updated Advisory Committee on Immunization Practices recommendations on hepatitis B vaccination, which expands the indicated age range for universal HepB vaccination to now include adults aged 19–59 years.CrossRef

29.

Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021 [Internet]. [cited 2023 Aug 7]. Available from: https://www.who.int/publications-detail-redirect/9789240027077

30.

Funk AL, Lu Y, Yoshida K, Zhao T, Boucheron P, van Holten J, et al. Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis. Lancet Infect Dis. 2021;21(1):70–84.PubMedCrossRef

31.

Dionne-Odom J, Cozzi GD, Franco RA, Njei B, Tita ATN. Treatment and prevention of viral hepatitis in pregnancy. Am J Obstet Gynecol. 2022;226(3):335–46.PubMedCrossRef

32.

Prevention of mother-to-child transmission of hepatitis B virus: guidelines on antiviral prophylaxis in pregnancy [Internet]. Geneva: World Health Organization; 2020 [cited 2023 Aug 13]. (WHO Guidelines Approved by the Guidelines Review Committee). Available from: http://www.ncbi.nlm.nih.gov/books/NBK561127/

33.

Terrault NA, Levy MT, Cheung KW, Jourdain G. Viral hepatitis and pregnancy. Nat Rev Gastroenterol Hepatol. 2021;18(2):117–30.PubMedCrossRef

34.

Jourdain G, Ngo-Giang-Huong N, Harrison L, Decker L, Khamduang W, Tierney C, et al. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. N Engl J Med. 2018;378(10):911–23.PubMedPubMedCentralCrossRef

35.

•• Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med. 2016;374(24):2324–34. This landmark study evaluated the use of tenofovir disoproxil fumarate during pregnancy for the prevention of mother-to-child transmission of hepatitis B virus (HBV).PubMedCrossRef

36.

Bierhoff M, Rijken MJ, Yotyingaphiram W, Pimanpanarak M, van Vugt M, Angkurawaranon C, et al. Tenofovir for prevention of mother to child transmission of hepatitis B in migrant women in a resource-limited setting on the Thailand-Myanmar border: a commentary on challenges of implementation. Int J Equity Health. 2020;19(1):156.PubMedPubMedCentralCrossRef

37.

Siberry GK, Jacobson DL, Kalkwarf HJ, Wu JW, DiMeglio LA, Yogev R, et al. Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy. Clin Infect Dis Off Publ Infect Dis Soc Am. 2015;61(6):996–1003.CrossRef

38.

Seidel V, Weizsäcker K, Henrich W, Rancourt RC, Bührer C, Krüger R, et al. Safety of tenofovir during pregnancy: early growth outcomes and hematologic side effects in HIV-exposed uninfected infants. Eur J Pediatr. 2020;179(1):99–109.PubMedCrossRef

39.

Li B, Liu Z, Liu X, Liu D, Duan M, Gu Y, et al. Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load. Hepatol Int. 2021;15(5):1103–8.PubMedCrossRef

40.

Zeng QL, Zhang HX, Zhang JY, Huang S, Li WZ, Li GM, et al. Tenofovir alafenamide for pregnant Chinese women with active chronic hepatitis B: a multicenter prospective study. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2022;20(12):2826-2837.e9.

41.

Chen R, Zou J, Long L, Huang H, Zhang M, Fan X, et al. Safety and efficacy of tenofovir alafenamide fumarate in early-middle pregnancy for mothers with chronic hepatitis B. Front Med. 2022;17(8):796901.CrossRef

42.

Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org, Badell ML, Prabhu M, Dionne J, Tita ATN, Silverman NS, et al. Society for Maternal-Fetal Medicine Consult Series #69: Hepatitis B in pregnancy: updated guidelines. Am J Obstet Gynecol. 2023;S0002–9378(23)02173–7.

43.

Zhang L, Tao Y, Woodring J, Rattana K, Sovannarith S, Rathavy T, et al. Integrated approach for triple elimination of mother-to-child transmission of HIV, hepatitis B and syphilis is highly effective and cost-effective: an economic evaluation. Int J Epidemiol. 2019;48(4):1327–39.PubMedCrossRef

44.

Wang L, Li J, Chen H, Li F, Armstrong GL, Nelson C, et al. Hepatitis B vaccination of newborn infants in rural China: evaluation of a village-based, out-of-cold-chain delivery strategy. Bull World Health Organ. 2007;85(9):688–94.PubMedPubMedCentralCrossRef

45.

Kolwaite AR, Xeuatvongsa A, Ramirez-Gonzalez A, Wannemuehler K, Vongxay V, Vilayvone V, et al. Hepatitis B vaccine stored outside the cold chain setting: a pilot study in rural Lao PDR. Vaccine. 2016;34(28):3324–30.PubMedPubMedCentralCrossRef

46.

Scott N, Palmer A, Morgan C, Lesi O, Spearman CW, Sonderup M, et al. Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study. Lancet Glob Health. 2018;6(6):e659–67.PubMedCrossRef

47.

Chotun N, Preiser W, van Rensburg CJ, Fernandez P, Theron GB, Glebe D, et al. Point-of-care screening for hepatitis B virus infection in pregnant women at an antenatal clinic: a South African experience. PLoS ONE. 2017;12(7):e0181267.PubMedPubMedCentralCrossRef

48.

World Health Organization. WHO guideline on the use of safety-engineered syringes for intramuscular, intradermal and subcutaneous injections in health care settings [Internet]. World Health Organization; 2016 [cited 2023 Aug 16]. 49 p. Available from: https://apps.who.int/iris/handle/10665/250144

49.

Pépin J, Abou Chakra CN, Pépin E, Nault V, Valiquette L. Evolution of the global burden of viral infections from unsafe medical injections, 2000–2010. PLoS ONE. 2014;9(6):e99677.PubMedPubMedCentralCrossRef

50.

Adewuyi EO, Auta A. Medical injection and access to sterile injection equipment in low- and middle-income countries: a meta-analysis of Demographic and Health Surveys (2010–2017). Int Health. 2019;12(5):388–94.PubMedCentralCrossRef

51.

Bahuguna P, Prinja S, Lahariya C, Dhiman RK, Kumar MP, Sharma V, et al. Cost-Effectiveness of therapeutic use of safety-engineered syringes in healthcare facilities in India. Appl Health Econ Health Policy. 2020;18(3):393–411.PubMedCrossRef

52.

Mostafa A, El-Sayed MH, El Kassas M, Elhamamsy M, Elsisi GH. Safety-engineered syringes: an intervention to decrease hepatitis C burden in developing countries-a cost-effectiveness analysis from Egypt. Value Health Reg Issues. 2019;19:51–8.PubMedCrossRef

53.

Gore C, Lazarus JV, Peck RJJ, Sperle I, Safreed-Harmon K. Unnecessary injecting of medicines is still a major public health challenge globally. Trop Med Int Health TM IH. 2013;18(9):1157–9.PubMedCrossRef

54.

Shing JZ, Ly KN, Xing J, Teshale EH, Jiles RB. Prevalence of hepatitis B virus infection among US adults aged 20–59 years with a history of injection drug use: National Health and Nutrition Examination Survey, 2001–2016. Clin Infect Dis Off Publ Infect Dis Soc Am. 2020;70(12):2619–27.CrossRef

55.

Yang J, Zhang Y, Luo L, Meng R, Yu C. Global mortality burden of cirrhosis and liver cancer attributable to injection drug use, 1990–2016: an age-period-cohort and spatial autocorrelation analysis. Int J Environ Res Public Health. 2018;15(1):170.PubMedPubMedCentralCrossRef

56.

van Santen DK, Boyd A, Matser A, Maher L, Hickman M, Lodi S, et al. The effect of needle and syringe program and opioid agonist therapy on the risk of HIV, hepatitis B and C virus infection for people who inject drugs in Amsterdam, the Netherlands: findings from an emulated target trial. Addict Abingdon Engl. 2021;116(11):3115–26.CrossRef

57.

Kåberg M, Karlsson N, Discacciati A, Widgren K, Weiland O, Ekström AM, et al. Significant decrease in injection risk behaviours among participants in a needle exchange programme. Infect Dis. 2020;52(5):336–46.CrossRef

58.

AlankoBlomé M, Björkman P, Flamholc L, Jacobsson H, Widell A. Vaccination against hepatitis B virus among people who inject drugs – a 20year experience from a Swedish needle exchange program. Vaccine. 2017;35(1):84–90.CrossRef

59.

Bowman S, Grau LE, Singer M, Scott G, Heimer R. Factors associated with hepatitis B vaccine series completion in a randomized trial for injection drug users reached through syringe exchange programs in three US cities. BMC Public Health. 2014;9(14):820.CrossRef

60.

Lloyd AR, Franco RA. Sexual transmission of viral hepatitis. Infect Dis Clin North Am. 2023;37(2):335–49.PubMedCrossRef

61.

Roberts H, Jiles R, Harris AM, Gupta N, Teshale E. Incidence and prevalence of sexually transmitted hepatitis B, United States, 2013–2018. Sex Transm Dis. 2021;48(4):305–9.PubMedPubMedCentralCrossRef

62.

Daka D, Hailemeskel G, Fenta DA. Prevalence of hepatitis B virus infection and associated factors among female sex workers using respondent-driven sampling in Hawassa City, Southern Ethiopia. BMC Microbiol. 2022;31(22):37.CrossRef

63.

Bitty-Anderson AM, Ferré V, Gbeasor-Komlanvi FA, Tchankoni MK, Sadio A, Salou M, et al. Prevalence of hepatitis B and C among female sex workers in Togo, West Africa. PLoS ONE. 2021;16(12):e0259891.PubMedPubMedCentralCrossRef

64.

Motta-Castro ARC, Kerr L, Kendall C, Mota RS, Guimarães MDC, Leal AF, et al. Hepatitis B prevalence among men who have sex with men in Brazil. Trop Med Infect Dis. 2023;8(4):218.PubMedPubMedCentralCrossRef

65.

Brandl M, Schmidt AJ, Marcus U, an der Heiden M, Dudareva S. Are men who have sex with men in Europe protected from hepatitis B? Epidemiol Infect. 2020;148: e27.PubMedPubMedCentralCrossRef

66.

van Rijckevorsel G, Whelan J, Kretzschmar M, Siedenburg E, Sonder G, Geskus R, et al. Targeted vaccination programme successful in reducing acute hepatitis B in men having sex with men in Amsterdam, the Netherlands. J Hepatol. 2013;59(6):1177–83.PubMedCrossRef

67.

Nguyen LH, Tran BX, Rocha LEC, Nguyen HLT, Yang C, Latkin CA, et al. A systematic review of eHealth interventions addressing HIV/STI prevention among men who have sex with men. AIDS Behav. 2019;23(9):2253–72.PubMedPubMedCentralCrossRef

68.

Nourimand F, Keramat A, Sayahi M, Bozorgian L, Hashempour Z. A systematic review of eHealth modes in preventing sexually transmitted infections. Indian J Sex Transm Dis AIDS. 2022;43(2):117–27.PubMedPubMedCentralCrossRef

69.

Hongjaisee S, Khamduang W, Sripan P, Choyrum S, Thepbundit V, Ngo-Giang-Huong N, et al. Prevalence and factors associated with hepatitis B and D virus infections among migrant sex workers in Chiangmai, Thailand: a cross-sectional study in 2019. Int J Infect Dis. 2020;1(100):247–54.CrossRef

70.

Mahapatra B, Walia M, Patel SK, Battala M, Mukherjee S, Patel P, et al. Sustaining consistent condom use among female sex workers by addressing their vulnerabilities and strengthening community-led organizations in India. PLoS ONE. 2020;15(7):e0235094.PubMedPubMedCentralCrossRef

71.

Zhang H, Hsieh E, Wang L, Liao S. HIV/AIDS Among Female Sex Workers in China: Epidemiology and Recent Prevention Strategies. Curr HIV/AIDS Rep. 2020;17(2):151–60.PubMedPubMedCentralCrossRef

72.

Mizushima D, Takano M, Aoki T, Ando N, Uemura H, Yanagawa Y, et al. Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men. Hepatol Baltim Md. 2023;77(6):2084–92.CrossRef

73.

Dolan K, Wirtz AL, Moazen B, Ndeffo-Mbah M, Galvani A, Kinner SA, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet Lond Engl. 2016;388(10049):1089–102.CrossRef

74.

Pashangzadeh S, SeyedAlinaghi S, Dadras O, Pashaei Z, Soleymanzadeh M, Barzegary A, et al. Prevalence of hepatitis in prisoners: a systematic review of current evidence. Infect Disord Drug Targets. 2022;22(8):61–72.PubMedCrossRef

75.

Christensen PB, Fisker N, Krarup HB, Liebert E, Jaroslavtsev N, Christensen K, et al. Hepatitis B vaccination in prison with a 3-week schedule is more efficient than the standard 6-month schedule. Vaccine. 2004;22(29–30):3897–901.PubMedCrossRef

76.

Stasi C, Monnini M, Cellesi V, Salvadori M, Marri D, Ameglio M, et al. Screening for hepatitis B virus and accelerated vaccination schedule in prison: a pilot multicenter study. Vaccine. 2019;37(11):1412–7.PubMedCrossRef

77.

Costumbrado J, Stirland A, Cox G, El-Amin AN, Miranda A, Carter A, et al. Implementation of a hepatitis A/B vaccination program using an accelerated schedule among high-risk inmates, Los Angeles County Jail, 2007–2010. Vaccine. 2012;30(48):6878–82.PubMedCrossRef

78.

Wirtz AL, Yeh PT, Flath NL, Beyrer C, Dolan K. HIV and viral hepatitis among imprisoned key populations. Epidemiol Rev. 2018;40(1):12–26.PubMedPubMedCentralCrossRef

79.

Scott N, McBryde E, Kirwan A, Stoové M. Modelling the impact of condom distribution on the incidence and prevalence of sexually transmitted infections in an adult male prison system. PLoS ONE. 2015;10(12):e0144869.PubMedPubMedCentralCrossRef

80.

Hutin Y, Nasrullah M, Easterbrook P, Nguimfack BD, Burrone E, Averhoff F, et al. Access to treatment for hepatitis B virus infection — worldwide, 2016. Morb Mortal Wkly Rep. 2018;67(28):773–7.CrossRef

81.

Razavi-Shearer D, Gamkrelidze I, Nguyen MH, Chen DS, Van Damme P, Abbas Z, et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383–403.CrossRef

82.

Liu J, Liang W, Jing W, Liu M. Countdown to 2030: eliminating hepatitis B disease. China Bull World Health Organ. 2019;97(3):230–8.PubMedCrossRef

83.

Tan M, Bhadoria AS, Cui F, Tan A, Van Holten J, Easterbrook P, et al. Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;6(2):106–19.PubMedPubMedCentralCrossRef

84.

Ye Q, Kam LY, Yeo YH, Dang N, Huang DQ, Cheung R, et al. Substantial gaps in evaluation and treatment of patients with hepatitis B in the US. J Hepatol. 2022;76(1):63–74.PubMedCrossRef

85.

• Nguyen VH, Le AK, Trinh HN, Chung M, Johnson T, Wong C, et al. Poor adherence to guidelines for treatment of chronic hepatitis B virus infection at primary care and referral practices. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2019;17(5):957-967.e7. This reference assesses rates of treatment evaluation and initiation in patients with chronic HBV infection from different practice settings in the U.S.

86.

Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection [Internet]. [cited 2023 Aug 22]. Available from: https://www.who.int/publications-detail-redirect/9789241549059

87.

Hill A, Gotham D, Cooke G, Bhagani S, Andrieux-Meyer I, Cohn J, et al. Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries. J Virus Erad. 2015;1(2):103–10.PubMedPubMedCentralCrossRef

88.

Dakin H, Bentley A, Dusheiko G. Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2010;13(8):922–33.CrossRef

89.

Dakin H, Sherman M, Fung S, Fidler C, Bentley A. Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective. Pharmacoeconomics. 2011;29(12):1075–91.PubMedCrossRef

90.

Ke W, Zhang C, Liu L, Gao Y, Yao Z, Ye X, et al. Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China. Hepatol Int. 2016;10(6):924–36.PubMedCrossRef

91.

Schmit N, Nayagam S, Lemoine M, Ndow G, Shimakawa Y, Thursz MR, et al. Cost-effectiveness of different monitoring strategies in a screening and treatment programme for hepatitis B in the Gambia. J Glob Health. 2023;20(13):04004.CrossRef

92.

Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022). Zhonghua Gan Zang Bing Za Zhi Zhonghua Ganzangbing Zazhi Chin J Hepatol. 2022;30(12):1309–31.

93.

Dieterich D, Graham C, Wang S, Kwo P, Lim YS, Liu CJ, et al. It is time for a simplified approach to hepatitis B elimination. Gastro Hep Adv. 2023;2(2):209–18.CrossRef

94.

Wong RJ, Kaufman HW, Niles JK, Kapoor H, Gish RG. Simplifying treatment criteria in chronic hepatitis B: reducing barriers to elimination. Clin Infect Dis Off Publ Infect Dis Soc Am. 2023;76(3):e791-800.CrossRef

Title: Hepatitis B Virus Elimination Strategies
Authors: Mimi Xu
Norah A. Terrault
Publication date: 21-02-2024
Publisher: Springer US
Keywords: Hepatitis B
Vaccination
Published in: Current Hepatology Reports / Issue 2/2024
Electronic ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-024-00658-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 2/2024

Perspective on Emerging Therapies to Achieve Functional Cure of Chronic Hepatitis B

Management of Hepatitis B in Pregnancy

Expanding the Donor Pool for Liver Transplantation: Assessing the Potential Use of HBV-Positive Allografts

A Review of Hepatitis B Reactivation Risk on Immunosuppressants with a Focus on Newer Immunomodulators

Acute Kidney Injury in Acute on Chronic Liver Failure Versus Decompensated Cirrhosis—What Is the Difference?

Treatment of Gastric Varices

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage